Description

Momelotinib Dihydrochloride is a high-purity, small molecule active pharmaceutical ingredient (API) belonging to the class of Janus kinase (JAK) inhibitors. This compound is of significant commercial and therapeutic interest for its targeted mechanism of action in clinical research and pharmaceutical development. It is primarily required by pharmaceutical companies, biotechnology research firms, and contract development and manufacturing organizations (CDMOs) engaged in the development of novel therapeutics for myelofibrosis and related hematological conditions.

Application

• Pharmaceutical API Synthesis: Serves as the critical active ingredient in the formulation of finished drug products for clinical and commercial use.
• Oncology Research: Used as a key reference standard and investigational compound in preclinical and clinical studies targeting JAK1/JAK2 pathways.
• Myelofibrosis Treatment Development: Central to R&D programs focused on developing therapies for myeloproliferative neoplasms, specifically for patients with anemia.
• Biochemical Assay Development: Employed in the creation of in-vitro screening assays to study JAK/STAT signaling inhibition and mechanism of action.
• Process Chemistry & Scale-Up: Used by CDMOs for process optimization, impurity profiling, and the scale-up of GMP manufacturing batches.
• Reference Standard: Provides a high-purity benchmark for quality control laboratories to validate analytical methods (HPLC, LC-MS) for drug substance testing.

Basic Information

Product Name	Momelotinib Dihydrochloride
CAS No.	1380317-28-1
Molecular Formula	C23H22N6O2 • 2HCl
Molecular Weight	503.39 g/mol (free base: 414.46)
Synonyms	GS-0387; CYT-387 Dihydrochloride; 9H-Purine-6-carboxamide, 4-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-N-3-pyridinyl-9H-purin-6-amine dihydrochloride; Momelotinib HCl; INCB-039110 Dihydrochloride; GS-0387 Dihydrochloride; CYT387 Dihydrochloride
EINECS	Contact for details

Quality Control

Our Momelotinib Dihydrochloride is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing to ensure identity, purity, and consistency, meeting the stringent requirements for pharmaceutical intermediates and APIs. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting results for assay, related substances, residual solvents, and other critical parameters. We support development with regulatory starting material (RSM) documentation packages.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or as indicated on the label or COA. This material is hygroscopic (moisture-sensitive) and must be kept in a dry environment. For long-term storage, consider desiccants or inert atmosphere to maintain stability.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥98.0% (anhydrous basis)
Water Content (KF)	≤2.0%
Residual Solvents (GC)	Meets ICH Q3C guidelines
Related Substances (HPLC)	Total impurities ≤2.0%; Any single unknown impurity ≤0.5%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.